Astrazeneca PLC

AZN | $68.36 -0.25% -0.25% 4M

(0.0% 1d) (3.7% 1m) (-8.8% 1y) (0.0% 2d) (0.0% 3d) (-1.0% 7d) (-41.8% volume)
Earnings Calendar:
Market Cap: $ 211,946,254,495
http://astrazeneca.com
Sec Filling | Patents | 70600 employees

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

cardiovascular respiratory urea renal metabolic

add to watch list Paper trade email alert is off

Novo Nordisk A/S

NVO | News | $122.75 -1.43% 0.0% 2.8M

Health Technology

(0.0% 1d) (-5.2% 1m) (-24.5% 1y) (0.0% 2d) (0.9% 3d) (0.0% 7d) (1.02% volume)
Earnings Calendar:
Market Cap: $ 421,661,962,000
http://www.novonordisk.com
Sec Filling | Patents | 43258 employees

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

obesity diabetes haemophilia insulin diabetic hormone growth hormone

add to watch list Paper trade email alert is off

Koninklijke Philips N.V.

PHG | News | $19.98 -0.84% 0.0% 500K

Health Technology

(0.0% 1d) (-3.1% 1m) (12.9% 1y) (0.0% 2d) (-1.3% 3d) (0.4% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 18,252,049,001
http://www.philips.com
Sec Filling | Patents | 80495 employees

Royal Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The Personal Health segment focuses on healthy living and preventative care. This segment comprises the Personal Care, Domestic Appliances, Oral Healthcare, and Mother & Child Care businesses. The Diagnosis & Treatment segment unites the businesses related to the promise of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatments. This segment comprises the Diagnostic Imaging, Ultrasound, Healthcare Informatics and Image-Guided Therapy businesses. The Connected Care & Health Informatics segment focuses on patient care solutions, advanced analytics and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways and leveraging provider-payer-patient business models. This segment comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, and Sleep & Respiratory Care businesses. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

respiratory optical royalties diagnostics treatment

add to watch list Paper trade email alert is off

Bio-Rad Laboratories, Inc.

BIO | $281.02 -3.38% -0.36% 370K

Health Technology

(0.0% 1d) (-13.0% 1m) (-39.8% 1y) (0.0% 2d) (0.0% 3d) (-2.6% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 8,439,443,418
http://www.bio-rad.com
Sec Filling | Patents | 8120 employees

(US) Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

diagnostics

add to watch list Paper trade email alert is off

Bristol-Myers Squibb Company

BMY | $48.3 0.96% -0.1% 11M

Health Technology

(0.0% 1d) (-6.8% 1m) (-30.9% 1y) (0.0% 2d) (0.0% 3d) (-0.0% 7d) (-0.1% volume)
Earnings Calendar: 2024-02-02
Market Cap: $ 97,892,445,935
http://www.bms.com
Sec Filling | Patents | 30000 employees

(US) Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.